Obesity increases production of myeloid cells by expanding myeloid progenitors and enhancing myelopoiesis, leading to elevated monocyte counts and a pro-inflammatory state. Weight loss (WL) improves some aspects of this inflammatory dysregulation, but whether different WL approaches—specifically a dual GIP/GLP-1 agonist (tirzepatide) versus caloric restriction (CR)—have distinct effects on hematopoietic stem/progenitor cells (HSPCs), hematopoiesis, and inflammatory cell output was not known.
The investigators compared hematopoietic compartments in lean mice, obese mice, and two groups of weight-reduced mice whose body weight loss was matched: one group treated with tirzepatide and the other subjected to calorie restriction (CR). Experiments included flow cytometry phenotyping and single-cell mRNA sequencing (scRNA-seq) of bone marrow HSPCs and mature blood mononuclear cells to define cell composition and transcriptional programs across conditions.
At equivalent amounts of weight loss, CR produced multilineage cytopenias, indicating a broad suppression of peripheral blood cell lineages. By contrast, tirzepatide-treated mice with matched WL did not show the same broad reductions; major blood lineages were preserved. Instead of global suppression, tirzepatide specifically reduced the numbers of classical inflammatory monocytes characterized as Ly6Chi CCR2+.
To probe mechanisms underlying these divergent outcomes, the authors performed scRNA-seq on bone marrow HSPCs and on mature mononuclear blood cells. This approach allowed cell-type–specific gene expression comparisons across lean, obese, CR, and tirzepatide-treated WL cohorts, and enabled inference of cell-cycle activity and metabolic program engagement at single-cell resolution.
HSPCs from CR mice exhibited suppressed gene sets associated with nutrient sensing, proliferation, and oxidative phosphorylation (OXPHOS), consistent with lower inferred cell-cycle activity in the CR condition. In contrast, tirzepatide-treated HSPCs showed attenuation of these suppressive signatures—suggesting preservation of progenitor cycling and activity despite weight reduction. Thus, CR and tirzepatide diverged in their effects on transcriptional programs linked to metabolism and proliferation within HSPCs.
Along progressive differentiation from HSPCs to mature blood monocytes, tirzepatide had a distinct pattern: OXPHOS-related gene expression was increasingly suppressed in more differentiated cells, and the maturation spectrum was shifted away from the classical Ly6Chi CCR2+ monocyte phenotype. This remodeling resulted in a selective reduction of inflammatory/classical monocytes without inducing the global cytopenias seen with CR. The data therefore indicate that tirzepatide selectively remodels the monocyte compartment while maintaining broader hematopoietic output.
The investigators assessed whether the tirzepatide-associated changes persisted after treatment cessation. Following six weeks of tirzepatide withdrawal accompanied by weight regain, Ly6Chi CCR2+ monocyte numbers rebounded to levels observed in obese mice. This reversibility suggests that the reduction of classical inflammatory monocytes depends on ongoing treatment and/or maintained weight-loss state rather than representing a permanent reprogramming.
These results indicate that WL modality differentially affects hematopoietic adaptation: caloric restriction associates with broad suppression of HSPC proliferation and multilineage cytopenias, whereas tirzepatide preserves progenitor cycling yet selectively remodels inflammatory monocytes—particularly classical Ly6Chi CCR2+ cells. The authors propose that classical monocytes are an effector population through which tirzepatide may attenuate obesity-associated inflammation.
Limitations and scope: the study was performed in mouse models; specific numerical data, detailed methods, and statistical analyses were reported in the source but are not reproduced here. The effect on monocytes was reversible after treatment withdrawal, indicating dependence on continued therapy or sustained WL.
Competing interests and funding: the source notes one author (JR) with multiple industry affiliations; other authors reported no competing interests. Funding sources declared in the original report included NIH grants and a foundation award as reported by the authors.